Abstract
Thiazide-induced potassium loss may contribute to new onset diabetes (NOD). KCNJ1 encodes a potassium channel and one study observed that a KCNJ1 single-nucleotide polymorphism (SNP) was associated with changes in fasting glucose (FG) during hydrochlorothiazide (HCTZ) treatment. We used linear regression to test association of KCNJ1 SNPs and haplotypes with FG changes during HCTZ treatment in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. We used logistic regression to test association of KCNJ1 variation with NOD in HCTZ-treated patients from the International Verapamil SR Trandolapril Study (INVEST). Multivariate regression analyses were performed by race/ethnicity with false discovery rate (FDR) correction. In PEAR blacks, a KCNJ1 SNP was associated with increased FG during HCTZ treatment (beta=8.47, PFDR=0.009). KCNJ1 SNPs and haplotypes were associated with NOD risk in all INVEST race/ethnic groups (strongest association: odds ratio 2.14 (1.31–3.53), PFDR=0.03). Our findings support that KCNJ1 variation is associated with HCTZ-induced dysglycemia and NOD.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB et al. Executive summary: Heart Disease and Stroke Statistics—2012 Update: a report from the American Heart Association. Circulation 2012; 125: 188–197.
Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43: 963–969.
Alderman MH, Cohen H, Madhavan S . Diabetes and cardiovascular events in hypertensive patients. Hypertension 1999; 33: 1130–1134.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–2572.
Carter BL, Einhorn PT, Brands M, He J, Cutler JA, Whelton PK et al. Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. Hypertension 2008; 52: 30–36.
Elliott WJ, Meyer PM . Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201–207.
Meigs JB, Cupples LA, Wilson PW . Parental transmission of type 2 diabetes: the Framingham Offspring Study. Diabetes 2000; 49: 2201–2207.
Bozkurt O, de Boer A, Grobbee DE, de Leeuw PW, Kroon AA, Schiffers P et al. Variation in Renin-Angiotensin system and salt-sensitivity genes and the risk of diabetes mellitus associated with the use of thiazide diuretics. Am J Hypertens 2009; 22: 545–551.
Maitland-van der Zee AH, Turner ST, Schwartz GL, Chapman AB, Klungel OH, Boerwinkle E . Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects. Am J Hypertens 2005; 18: 1077–1083.
Irvin MR, Lynch AI, Kabagambe EK, Tiwari HK, Barzilay JI, Eckfeldt JH et al. Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study. J Hypertens 2010; 28: 2076–2083.
Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL . Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006; 48: 219–224.
Shafi T, Appel LJ, Miller ER, Klag MJ, Parekh RS . Changes in serum potassium mediate thiazide-induced diabetes. Hypertension 2008; 52: 1022–1029.
Johnson JA, Boerwinkle E, Zineh I, Chapman AB, Bailey K, Cooper-DeHoff RM et al. Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J 2009; 157: 442–449.
Pepine CJ, Handberg-Thurmond E, Marks RG, Conlon M, Cooper-DeHoff R, Volkers P et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension. J Am Coll Cardiol 1998; 32: 1228–1237.
Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805–2816.
Cooper-Dehoff R, Cohen JD, Bakris GL, Messerli FH, Erdine S, Hewkin AC et al. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol 2006; 98: 890–894.
Cooper-DeHoff RM, Handberg EM, Mancia G, Zhou Q, Champion A, Legler UF et al. INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study. Expert Rev Cardiovasc Ther 2009; 7: 1329–1340.
Keating BJ, Tischfield S, Murray SS, Bhangale T, Price TS, Glessner JT et al. Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS One 2008; 3: e3583.
Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559–575.
Cooper-DeHoff RM, Aranda JM, Gaxiola E, Cangiano JL, Garcia-Barreto D, Conti CR et al. Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients—findings from the International Verapamil SR/Trandolapril Study (INVEST). Am Heart J 2006; 151: 1072–1079.
Conway J, Lauwers P . Hemodynamic and hypotensive effects of long-term therapy with chlorothiazide. Circulation 1960; 21: 21–27.
Barrett JC, Fry B, Maller J, Daly MJ . Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263–265.
Welling PA, Ho K . A comprehensive guide to the ROMK potassium channel: form and function in health and disease. Am J Physiol Renal Physiol 2009; 297: F849–F863.
Braun M, Ramracheya R, Bengtsson M, Zhang Q, Karanauskaite J, Partridge C et al. Voltage-gated ion channels in human pancreatic beta-cells: electrophysiological characterization and role in insulin secretion. Diabetes 2008; 57: 1618–1628.
Chatterjee R, Yeh HC, Shafi T, Selvin E, Anderson C, Pankow JS et al. Serum and dietary potassium and risk of incident type 2 diabetes mellitus: The Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2010; 170: 1745–1751.
Smith SM, Anderson SD, Wen S, Gong Y, Turner ST, Cooper-Dehoff RM et al. Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. Pharmacotherapy 2009; 29: 1157–1165.
Goldman N, Lin IF, Weinstein M, Lin YH . Evaluating the quality of self-reports of hypertension and diabetes. J Clin Epidemiol 2003; 56: 148–154.
Aguilar D, Solomon SD, Kober L, Rouleau JL, Skali H, McMurray JJ et al. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation 2004; 110: 1572–1578.
Bosch J, Lonn E, Pogue J, Arnold JM, Dagenais GR, Yusuf S . Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005; 112: 1339–1346.
Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH et al. Ramipril and the development of diabetes. JAMA 2001; 286: 1882–1885.
Acknowledgements
This work is supported by a grant from the National Institutes of Health (Bethesda, MD, USA), grant U01 GM074492, funded as part of the Pharmacogenetics Research Network. Additional support for this work includes: National Institutes of Health grants R01 HL74730, K23 grants HL091120 (AL Beitelshees) and HL086558 (RM Cooper-DeHoff); NIH CTSA grants UL1-RR092890 (University of Florida), UL1-RR025008 (Emory University) and UL1-RR024150 (Mayo Clinic); and grants from Abbott Laboratories, the University of Florida Opportunity Fund.and the Mayo Foundation. The project described was supported by Award Number TL1RR029888 from the National Center for Research Resources (JH Karnes). We thank Brian Gawronski, Ben Burkley, Lynda Stauffer and Cheryl Galloway for processing and genotyping samples, the PEAR study physicians Drs George Baramidze, Carmen Bray, Kendall Campbell, R Whit Curry, Frederic Rabari-Oskoui, Dan Rubin and Seigfried Schmidt, and the patients who participated in PEAR and INVEST-GENES.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Drs Johnson, Pepine, Cooper-DeHoff and Langaee have received funding from Abbott Laboratories. The other authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the The Pharmacogenomics Journal website
Supplementary information
PowerPoint slides
Rights and permissions
About this article
Cite this article
Karnes, J., McDonough, C., Gong, Y. et al. Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment. Pharmacogenomics J 13, 430–436 (2013). https://doi.org/10.1038/tpj.2012.34
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/tpj.2012.34
Keywords
This article is cited by
-
Association of polymorphisms of calcium reabsorption genes SLC12A1, KCNJ1 and SLC8A1 with colorectal adenoma
Journal of Cancer Research and Clinical Oncology (2023)
-
Genome-wide association study identifies pharmacogenomic loci linked with specific antihypertensive drug treatment and new-onset diabetes
The Pharmacogenomics Journal (2018)
-
Drug-induced hyperglycaemia and diabetes: pharmacogenomics perspectives
Archives of Pharmacal Research (2018)
-
Transethnic meta-analysis suggests genetic variation in the HEME pathway influences potassium response in patients treated with hydrochlorothiazide
The Pharmacogenomics Journal (2015)
-
Pharmacogenomics of Hypertension and Heart Disease
Current Hypertension Reports (2015)